Treatment of non-small-cell lung cancer with vinblastine and very high-dose cisplatin. A Southwest Oncology Group study

Steven M. Grunberg, John J. Crowley, Robert B Livingston, Franco M. Muggia, John S. MacDonald, Stephen K. Williamson, Ronald L. Stephens

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Suggestions of a dose-response effect for cisplatin in non-small-cell lung cancer have contributed to the development of very high-dose cisplatin regimens (200 mg/m2 per cycle). We treated 53 eligible patients with metastatic or recurrent non-small-cell lung cancer with a combination of 100 mg/m2 cisplatin and 4 mg/m2 vinblastine, each given on days 1 and 8 of a 28-day cycle. We observed no complete response and 4 partial responses (8%). Median survival was 6 months. Toxicities of grade III or greater included leukopenia (11 cases), nausea/vomiting (6 cases), thrombocytopenia (2 cases), anemia (2 cases), and elevation of transaminase (1 case). Neurotoxicity has been reported to be a major problem in several other very high-dose cisplatin regimens. The low level of neurotoxicity observed in this study may be attributable to the median cumulative cisplatin dose of <600 mg/m2. This vinblastine/very high-dose cisplatin regimen showed minor activity against non-small-cell lung cancer. The level of activity did not surpass that of standard-dose (100 mg/m2 per cycle) cisplatin-containing regimens.

Original languageEnglish (US)
Pages (from-to)211-213
Number of pages3
JournalCancer Chemotherapy and Pharmacology
Volume28
Issue number3
DOIs
StatePublished - May 1991
Externally publishedYes

Fingerprint

Oncology
Vinblastine
Non-Small Cell Lung Carcinoma
Cisplatin
Cells
Therapeutics
Leukopenia
Transaminases
Nausea
Vomiting
Toxicity
Anemia
Survival

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

Treatment of non-small-cell lung cancer with vinblastine and very high-dose cisplatin. A Southwest Oncology Group study. / Grunberg, Steven M.; Crowley, John J.; Livingston, Robert B; Muggia, Franco M.; MacDonald, John S.; Williamson, Stephen K.; Stephens, Ronald L.

In: Cancer Chemotherapy and Pharmacology, Vol. 28, No. 3, 05.1991, p. 211-213.

Research output: Contribution to journalArticle

Grunberg, Steven M. ; Crowley, John J. ; Livingston, Robert B ; Muggia, Franco M. ; MacDonald, John S. ; Williamson, Stephen K. ; Stephens, Ronald L. / Treatment of non-small-cell lung cancer with vinblastine and very high-dose cisplatin. A Southwest Oncology Group study. In: Cancer Chemotherapy and Pharmacology. 1991 ; Vol. 28, No. 3. pp. 211-213.
@article{03e2e736fc18445c9d99eeb6c75dc50c,
title = "Treatment of non-small-cell lung cancer with vinblastine and very high-dose cisplatin. A Southwest Oncology Group study",
abstract = "Suggestions of a dose-response effect for cisplatin in non-small-cell lung cancer have contributed to the development of very high-dose cisplatin regimens (200 mg/m2 per cycle). We treated 53 eligible patients with metastatic or recurrent non-small-cell lung cancer with a combination of 100 mg/m2 cisplatin and 4 mg/m2 vinblastine, each given on days 1 and 8 of a 28-day cycle. We observed no complete response and 4 partial responses (8{\%}). Median survival was 6 months. Toxicities of grade III or greater included leukopenia (11 cases), nausea/vomiting (6 cases), thrombocytopenia (2 cases), anemia (2 cases), and elevation of transaminase (1 case). Neurotoxicity has been reported to be a major problem in several other very high-dose cisplatin regimens. The low level of neurotoxicity observed in this study may be attributable to the median cumulative cisplatin dose of <600 mg/m2. This vinblastine/very high-dose cisplatin regimen showed minor activity against non-small-cell lung cancer. The level of activity did not surpass that of standard-dose (100 mg/m2 per cycle) cisplatin-containing regimens.",
author = "Grunberg, {Steven M.} and Crowley, {John J.} and Livingston, {Robert B} and Muggia, {Franco M.} and MacDonald, {John S.} and Williamson, {Stephen K.} and Stephens, {Ronald L.}",
year = "1991",
month = "5",
doi = "10.1007/BF00685511",
language = "English (US)",
volume = "28",
pages = "211--213",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Treatment of non-small-cell lung cancer with vinblastine and very high-dose cisplatin. A Southwest Oncology Group study

AU - Grunberg, Steven M.

AU - Crowley, John J.

AU - Livingston, Robert B

AU - Muggia, Franco M.

AU - MacDonald, John S.

AU - Williamson, Stephen K.

AU - Stephens, Ronald L.

PY - 1991/5

Y1 - 1991/5

N2 - Suggestions of a dose-response effect for cisplatin in non-small-cell lung cancer have contributed to the development of very high-dose cisplatin regimens (200 mg/m2 per cycle). We treated 53 eligible patients with metastatic or recurrent non-small-cell lung cancer with a combination of 100 mg/m2 cisplatin and 4 mg/m2 vinblastine, each given on days 1 and 8 of a 28-day cycle. We observed no complete response and 4 partial responses (8%). Median survival was 6 months. Toxicities of grade III or greater included leukopenia (11 cases), nausea/vomiting (6 cases), thrombocytopenia (2 cases), anemia (2 cases), and elevation of transaminase (1 case). Neurotoxicity has been reported to be a major problem in several other very high-dose cisplatin regimens. The low level of neurotoxicity observed in this study may be attributable to the median cumulative cisplatin dose of <600 mg/m2. This vinblastine/very high-dose cisplatin regimen showed minor activity against non-small-cell lung cancer. The level of activity did not surpass that of standard-dose (100 mg/m2 per cycle) cisplatin-containing regimens.

AB - Suggestions of a dose-response effect for cisplatin in non-small-cell lung cancer have contributed to the development of very high-dose cisplatin regimens (200 mg/m2 per cycle). We treated 53 eligible patients with metastatic or recurrent non-small-cell lung cancer with a combination of 100 mg/m2 cisplatin and 4 mg/m2 vinblastine, each given on days 1 and 8 of a 28-day cycle. We observed no complete response and 4 partial responses (8%). Median survival was 6 months. Toxicities of grade III or greater included leukopenia (11 cases), nausea/vomiting (6 cases), thrombocytopenia (2 cases), anemia (2 cases), and elevation of transaminase (1 case). Neurotoxicity has been reported to be a major problem in several other very high-dose cisplatin regimens. The low level of neurotoxicity observed in this study may be attributable to the median cumulative cisplatin dose of <600 mg/m2. This vinblastine/very high-dose cisplatin regimen showed minor activity against non-small-cell lung cancer. The level of activity did not surpass that of standard-dose (100 mg/m2 per cycle) cisplatin-containing regimens.

UR - http://www.scopus.com/inward/record.url?scp=0025783769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025783769&partnerID=8YFLogxK

U2 - 10.1007/BF00685511

DO - 10.1007/BF00685511

M3 - Article

C2 - 1649706

AN - SCOPUS:0025783769

VL - 28

SP - 211

EP - 213

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 3

ER -